Neal Rosen

发表

Robert W. Lindeman, Bhagirath Narahari, Rahul Simha, 2004, International Conference on Wireless Networks.

Feedback and Redundancy in Oncoprotein Activated Signaling Pathways--Role in transformation and implications for therapy

Neal Rosen, 2009 .

SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent Cancers

Sarat Chandarlapaty, Neal Rosen, David B. Solit, 2008, Clinical Cancer Research.

Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors

Neal Rosen, Steven M Larson, David B Solit, 2004, Nature Biotechnology.

mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.

Sarat Chandarlapaty, Maurizio Scaltriti, Neal Rosen, 2011, Cancer discovery.

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.

Sarat Chandarlapaty, Neal Rosen, Peter T. Scardino, 2011, Cancer cell.

Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent

Neal Rosen, F. Hartl, N. Rosen, 1997, Cell.

Targeted cancer therapies

Neal Rosen, Li Yan, Carlos Arteaga, 2011, Chinese journal of cancer.

Hsp90: a novel target for cancer therapy.

Neal Rosen, David B Solit, N. Rosen, 2006, Current topics in medicinal chemistry.

RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF

Chao Zhang, Neal Rosen, Kevan M. Shokat, 2010, Nature.

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

Levi A Garraway, Kwok-Kin Wong, Neal Rosen, 2012, Cancer discovery.

Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer.

Ritika Kundra, Ahmet Zehir, Jianjiong Gao, 2018, Cancer cell.

Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90.

Gabriela Chiosis, Neal Rosen, N. Rosen, 2005, Journal of medicinal chemistry.

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

Gordon B Mills, Neal Rosen, Francesco Hofmann, 2006, Cancer research.

Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids.

George Sgouros, Neal Rosen, Glenn Heller, 2003, Cancer research.

BRAF mutation predicts sensitivity to MEK inhibition

Todd R. Golub, Gad Getz, Andrea Basso, 2006, Nature.

Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.

Mithat Gonen, Sarat Chandarlapaty, Neal Rosen, 2008, Cancer research.

Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling

Hans E. Huber, Sarat Chandarlapaty, Neal Rosen, 2008, PloS one.

The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.

Neal Rosen, David B Solit, Q. She, 2005, Cancer cell.

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

Tom Misteli, Mark C. Kelley, Neal Rosen, 2011, Nature.

Efficacy of MEK Inhibition in Patients with Histiocytic Neoplasms

Ahmet Dogan, Omar Abdel-Wahab, Alexia Iasonos, 2019, Nature.

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor

Elisa de Stanchina, Neal Rosen, Kevan M. Shokat, 2016, Nature.

Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice

Emma Lundsmith, Samuel Refetoff, Neal Rosen, 2011, Proceedings of the National Academy of Sciences.

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients

Sarat Chandarlapaty, Violeta Serra, Maurizio Scaltriti, 2011, Proceedings of the National Academy of Sciences.

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.

Sarat Chandarlapaty, Violeta Serra, Maurizio Scaltriti, 2011, Cancer cell.

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.

Ronglai Shen, Jorge S. Reis-Filho, Nikolaus Schultz, 2018, Cancer cell.

Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.

Lu Wang, Elisa de Stanchina, Neal Rosen, 2017, Cancer research.

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

Neal Rosen, N. Rosen, P. Lito, 2016, Science.

Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.

Christof Fellmann, Scott Lowe, Neal Rosen, 2014, Cancer cell.

BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

Gabriela Chiosis, Neal Rosen, N. Rosen, 2002, Blood.

Genetic predictors of MEK dependence in non-small cell lung cancer.

William Pao, Barry S Taylor, Neal Rosen, 2008, Cancer research.

Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.

Simon T Barry, Elisa de Stanchina, Sarat Chandarlapaty, 2015, Cancer cell.

BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.

Junfeng Xia, Peilin Jia, William Pao, 2012, Cancer discovery.

Drugging the Cancer Chaperone HSP90

Paul Workman, Neal Rosen, N. Rosen, 2007, Annals of the New York Academy of Sciences.

Genomic complexity and AKT dependence in serous ovarian cancer.

Chris Sander, Barry S Taylor, Nikolaus Schultz, 2012, Cancer discovery.

HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab

Alison Stopeck, Sarat Chandarlapaty, Neal Rosen, 2011, Clinical Cancer Research.

PTEN is a protein tyrosine phosphatase for IRS1

Xuejun Jiang, Sarat Chandarlapaty, Neal Rosen, 2014, Nature Structural &Molecular Biology.